Pricing Log in Create free account
Friday 6 November 2026 Export AMRX’s income statement to Excel — free account

AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.

Revenue
+9.96%
EPS
+267.0%
Free cash flow
−50.9%
Total debt
+23.8%

Quarter to September 2026, against a year earlier

20.25 0.80 +4.11%
Market cap
$6.8B
P/E
36.9×
Fwd P/E
44.2×
Dividend yield
—
F-score
7/9
Altman Z
1.94
Beneish M
−2.68
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

AMNEAL PHARMACEUTICALS, INC. (AMRX) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, AMNEAL PHARMACEUTICALS, INC. (AMRX) trades at a EV/Sales of 3.0×. Over the past ten years it has ranged from 1.2× (April 2023) to 4.5× (August 2018); the current reading is higher than 93% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 2.1× 17.97%
FY2024 1.7× 16.10%
FY2023 1.5× 10.56%
FY2022 1.4× (11.27%)
FY2021 1.5× (4.76%)
FY2020 1.6× (17.69%)
FY2019 2.0× (22.57%)
FY2018 2.5× 61.17%
FY2017 1.6× 0.00%
FY2016 1.6× 0.00%

Quarterly newest first

Period EV/Sales Change
Sep 2026 3.1× 18.32%
Jun 2026 2.6× 23.94%
Mar 2026 2.1× 1.41%
Dec 2025 2.1× 10.11%
43 more quarters

Against its own ten years

Low 1.2× High 4.5×
Ten-year median 1.7×
Current reading's percentile 93

EV/Sales against peers

Company EV/Sales
HIMS Hims & Hers Health, Inc. compare 2.4×
SUPN Indivior Pharmaceuticals Inc. compare 2.9×
AMRX AMNEAL PHARMACEUTICALS, INC. 3.0×
ELAN Elanco Animal Health Incorporated compare 3.0×
RDY Dr. Reddy's Laboratories Ltd compare 3.6×
LNTH Lantheus Holdings, Inc. compare 4.1×
ALKS Alkermes plc compare 4.7×
KNSA Kiniksa Pharmaceuticals International, plc compare 6.7×
LQDA Liquidia Corporation compare 8.6×
Drug Manufacturers Specialty & Generic industry median 2.9×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on AMRX